Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors

Industry Veteran with Business Development and Transactional Expertise Joins Eiger Board of Directors

19-Aug-2009 - Eiger BioPharmaceuticals, Inc. announced the appointment of Paul Truexto its Board of Directors. Truex is the founder, President and CEO of Anthera Pharmaceuticals - a private pharmaceutical company focused on the development of anti-inflammatory products for life threatening cardiovascular and ...

Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial

Proof of Concept Study Investigating NS4B-RNA Binding Inhibitor

13-Aug-2009 - Eiger BioPharmaceuticals, Inc. announced that the first patients have been dosed in a clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial, run in centers in Australia and New Zealand, will investigate the antiviral effect of clemizole monotherapy in the ...

Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University

05-Aug-2009 - Eiger BioPharmaceuticals, Inc. announced that it has licensed the exclusive worldwide rights to novel Hepatitis C Virus (HCV) technology from Stanford University. This technology, discovered in the lab of Stanford scientist and Eiger founder Dr. Jeffrey Glenn, M.D., Ph.D., is focused on a variety ...